Skip to main content
. 2017 Jun 4;2017:7194927. doi: 10.1155/2017/7194927

Figure 3.

Figure 3

Rate of patients with neovascular age-related macular degeneration aged ≥90 years that experience a loss of ≥15 ETDRS letters in best-corrected visual acuity during treatment with either Aflibercept (red) or Ranibizumab (blue).